Monday, 27 October 2014 - Wednesday, 29 October 2014
J2J PROGRAMME ROOM (Closed meeting)
The National Press Foundation and The Union are offering the 6th annual Journalist-to-Journalist (J2J) training on lung health issues at the World Conference. The training runs from 27-29 November, after which the journalists participate in the conference and post news stories from the venue. The training is designed for working journalists who want to increase their knowledge and skills they need to develop informed stories on lung health and related issues, such as the social, political and public health impact of lung disease. Sessions also cover the latest research, solutions and innovations that are in the pipeline.
Coordinators: Bob Meyers, Linda Streitfeld, National Press Foundation (USA); Paul Jensen, Katia Yezli, The Union
Tuesday, 28 October 2014
STRATEGIC MEETING ON WAYS FORWARD: TOBACCO CONTROL (Closed meeting)
Coordinator: Kayleigh Bleymann (UK)
Chair: Myra Wisotsky (USA)
CREATION OF A PLATFORM TO STORE AND SHARE TB CLINICAL TRIAL DATA (Closed meeting)
World Health Organisation
The overall objective of this initiative is to create a technical platform for sharing, combining and interrogating TB clinical trial databases in an efficient, ethical and sustainable manner; and use recent data sets testing fluoroquinolones in first line TB therapy (RIFAQUIN, OFLOTUB, REMOX trials) as a proof of principle for the merits of such a technical platform.
Coordinator: Corinne Merle (Switzerland)
Wednesday, 29 October 2014
NEW FUNDING MODEL OF THE GLOBAL FUND (Meeting open to all delegates)
World Health Organisation GTB/TSC/TBTEAM
Time: 9:00 - 17:00
GF New Funding Model – Concept note development and technical support from TB partners: what support was provided, what worked well, what were the challenges and what can be done better, lessons learnt.
Coordinator: Malgorzata Grzemska (Switzerland)
ANNUAL MEETING OF THE STOP TB PARTNERSHIP NEW DIAGNOSTICS WORKING GROUP
(Meeting open to all delegates)
“How can countries effectively use genotypic methods for managing MDR-TB?”
Time: 9:00 - 12:30
In this meeting we will review activities by the New Diagnostics Working Group as a coordination and communication platform to enable effective collaboration of stakeholders for accelerating progress in TB diagnostic research and development. We will more particularly report outcomes of recent meetings that the NDWG convened with partners to facilitate sharing and integration of sequencing data and to build consensus on high-priority Target Product Profiles. The session will also present progress in biomarker research for development of paediatric TB diagnostics, as well as latest study results on new technologies for multiplex drug susceptibility testing and for improved detection of TB at point-of-care and microscopy centre levels.
In the second part of the session a panel of clinical and laboratory experts will explore the state of genotypic and phenotypic testing in the context of low- and middle-income countries with a high burden of MDR-TB. While the knowledge correlating phenotypic and genotypic methods is rapidly evolving and promises to transform detection of drug resistance, the evidence to recommend genotypic methods as a replacement for phenotypic drug susceptibility testing is not yet available. The session will provide perspectives for considering genotyping approaches as the only feasible solution for high-burden countries which don’t have sufficient capacity for phenotypic testing. The panel will also discuss the challenges related to scaling-up genotypic methods into national guidance for treatment and management of MDR-TB in the low income setting.
Coordinators: John Ridderhof, CDC, NDWG Core Group, and Alessandra Varga, FIND, NDWG Secretariat
Chairs: Catharina Boehme, FIND, and Daniela Cirillo, San Raffaele Scientific Institute, NDWG Co-Chairs
FIND SYMPOSIUM (Meeting open to all delegates)
“Partnerships driving innovative diagnostic solutions in support of TB elimination”
Time: 13:30 - 17:00
The first part of the symposium will provide an update on the TB diagnostics pipeline. Presentations will highlight how FIND and partners are addressing diverse diagnostic challenges to support the 2020 Global targets for TB prevention, care and control. Speakers will report recent results of studies on promising technologies for case detection at point-of-care level for all populations, including children and people living with HIV, as well as on molecular solutions for improved identification of resistance to first- and second-line drugs.
In the second part of the session, a panel discussion on the theme of “Connected diagnostics: opportunities in overcoming bottlenecks in delivery” will follow an overview of current e-health efforts in diagnostics. The panel of international experts will include representatives of the public health sector and non-governmental organizations that are leading pioneer projects applying mobile and information technologies to healthcare in low- and middle-income countries, as well as companies providing solutions in this area. Panelists will discuss the potential of connectivity for improving TB diagnosis to effectively and affordably reach the estimated three million people that every year fail to access quality care.
Coordinator: Alessandra Varga, FIND (Switzerland),
Chair: Dr. Catharina Boehme, Chief Executive Officer, FIND, (Switzerland)
Thursday, 30 October 2014
RESIST-TB ANNUAL MEETING (Meeting open to all delegates)
This meeting is open to all interested in learning about clinical trials to improve the treatment of patients with MDR-TB and other work of RESIST-TB to advance the MDR-TB treatment agenda. This meeting will cover: 1) Clinical trials of MDR-TB; 2) Effect of GeneXpert on increasing MDR-TB diagnosis; 3) Availability of new drugs through Compassionate Use and Expanded Access. The event will conclude with an update on the STREAM trial and STREAM Stage II plans for bedaquiline containing regimens, presented by Drs. Andrew Nunn and Sarah Meredith.
Coordinator: Carly Rodriguez (USA)
Chair: C. Robert Horsburgh Jr, Boston University School of Public Health (USA)
FRIENDS OF PAKISTAN (Meeting open to all delegates)
"Friends of Pakistan is an annual meeting of national and international partners, collaborating organizations and individuals working with National TB control program in Pakistan. The meeting provides opportunity to share progress, highlight challenges and identify opportunities in TB control in Pakistan, one of the top 10 TB high burden countries in the world. The meeting is open to all participants;
Coordinator: Ejaz Qadeer, National TB Control Programme (Pakistan)
Friday , 31 October 2014
POTENTIAL OF INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) IN PATIENT-FRIENDLY TB CARE AND ADHERENCE MONITORING IN INDIA (Closed meeting)
To bring together a group of ICT and health experts from across the globe to discuss the role of ICT in healthcare in India, with a focus on TB treatment adherence. The meeting will be hosted by the National Forum on Tuberculosis, India.
Chair: Dalbir Singh
TUBERCULOSIS INFECTION CONTROL CONSULTATION MEETING: WHAT ARE HIGH BURDEN COUNTRIES DOING AND HOW CAN THESE EFFORTS BE STRENGTHENED?
(Meeting open to all delegates)
This facilitated TB IC consultation will engage the panel, composed of country representatives and TB IC experts, and the audience in a discussion on the best TBIC practices currently being implemented in-country, the TB IC tools currently being used and available for adaptation, and the best practices in scaling-up TBIC activities, including healthcare worker surveillance.
A summary report from this consultation will be prepared and provided to the sponsors and other governmental entities involved in global TB prevention and control.
Background: TB infection control (TBIC) is an important but neglected aspect of TB prevention, diagnosis and treatment. Absence of effective TBIC has led to outbreaks of drug-susceptible and drug-resistant TB in inpatient and outpatient settings causing unnecessary and preventable morbidity and mortality among patients and health care workers (HCWs). HCWs are exposed to TB in their work place settings and have a higher incidence of TB than the general population.
HIV infected individuals are more vulnerable to TB when their cellular immune systems decline, both because they reactivate latent TB and because they progress rapidly from infection to disease when exposed. The nosocomial transmission of multi-drug resistant (MDR) and extensively drug resistant (XDR) TB among persons ill with AIDS in hospitals and congregate settings has resulted in extremely high case fatality rates.
Coordinator: Susan A. Maloney, MD, MHSc; Global TB Coordinator, Office of the Director, Center for Global Health, US Centers for Disease Control and Prevention